Clinical Trial: Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: A Prospective, Open-label Trial of Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children

Brief Summary: The purpose of this study is planned to investigate whether small doses of methylprednisolone pulse macrolide therapy can relieve symptoms,chest X-rays faster than macrolide alone therapy for refractory mycoplasma pneumoniae pneumonia(MPP) .

Detailed Summary:

Corticosteroid has been used in adulthood refractory MPP with satisfactory efficacy. But there were few studies about the use of corticosteroid in children with refractory MPP. Lee KY et al indicated oral prednisolone of 1 mg/kg/ day for 1 week be useful for children with severe MPP. Akihiro T et al demonstrated that intravenously administered methylprednisolone at a dose of 30 mg/kg once daily for 3 consecutive days had an efficacious treatment for children with refractory MPP.But the methods of corticosteroid use, such as the dosage, administration route, duration of treatment have not been well understood. So in this study, we planned to investigate whether small doses of methylprednisolone pulse macrolide therapy can relieve symptoms,chest X-rays faster than macrolide alone therapy for refractory mycoplasma pneumoniae pneumonia in a prospective, open-label fashion.

PMID: 11096025 PMID: 18033831 PMID: 10434547 PMID: 16437541 PMID: 18656264


Sponsor: Chongqing Medical University

Current Primary Outcome: efficacy of methylprednisolone pulse macrolide therapy for children with refractory MPP. [ Time Frame: 3-year ]

compare the temperature , infiltration absorption,atelectasis resolution, pleural effusion disappearance,serum levels of ferritin and LDH between methylprednisolone pulse macrolide therapy group and macrolide therapy group .


Original Primary Outcome: Same as current

Current Secondary Outcome: safety of methylprednisolone pulse macrolide therapy for children with refractory MPP. [ Time Frame: 3-year ]

observe the further complications of infection between methylprednisolone pulse macrolide therapy group and macrolide therapy group .


Original Secondary Outcome: Same as current

Information By: Chongqing Medical University

Dates:
Date Received: October 6, 2010
Date Started: May 2007
Date Completion:
Last Updated: October 7, 2010
Last Verified: May 2007